Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
The European Journal of Health Economics
Published in: The European Journal of Health Economics 7/2016

01-09-2016 | Original Paper

Multiple sclerosis: relapses, resource use, and costs

Authors: A. J. Hawton, C. Green

Published in: The European Journal of Health Economics | Issue 7/2016

Login to get access

Abstract

Background

Relapses can have a major impact on the lives of people with multiple sclerosis (MS), and yet relapse-related healthcare costs have received little attention. This has limited cost-effectiveness analyses of treatments for MS and hampered decision-making regarding the funding of MS healthcare services.

Objective

To describe health/social care resource use and costs according to the frequency, severity, and endurance of MS relapses.

Methods

Data from the prospective, longitudinal UK South West Impact of Multiple Sclerosis cohort were used. A total of 11,800 questionnaires from 1441 people with MS were available, including data on relapses, contacts with health/social care professionals, and other MS-related resource use.

Results

The mean (SD) 6-monthly MS-related health/social care cost for individuals who reported a relapse was £519 (£949), compared to £229 (£366) for those who had not did report a relapse. Care costs varied widely dependent on the characteristics of the relapse. The mean (SD) cost when a relapse was not treated with steroids was £381 (£780), whilst the equivalent cost was £3579 (£1727) when a relapse resulted in hospitalization.

Conclusions

The impact of relapses on health and social care resources and costs differs according to their frequency, length, and severity. The data provided here can be used in cost-effectiveness analyses and to inform decision-making regarding healthcare provision for people with this condition.
Literature
1.
Hauser, S.: Multiple sclerosis and other demyelinating diseases. In: Isselbacher, K., Braunwald, E., Wilson, J. (eds.) Harrison’s Principles of Internal Medicine. McGraw-Hill, New York (1994)
2.
Noseworthy, J., Lucchinetti, C., Rodriguez, M., Weinshenker, B.: Medical progress: multiple sclerosis. N. Engl. J. Med. 343, 938–952 (2000)CrossRefPubMed
3.
Multiple Sclerosis International Federation: Atlas of MS 2013. Multiple Sclerosis International Federation, London (2013)
4.
Kobelt, G., Berg, J., Lindgren, P., Anten, B., Ekman, M., Jongen, P.J.H., Polman, C., Uitdehaag, B.: Costs and quality of life in multiple sclerosis in The Netherlands. Eur. J. Health. Econ. 7(2 SUPPL.), S55–S64 (2006)CrossRefPubMed
5.
Kobelt, G., Berg, J., Lindgren, P., Battaglia, M., Lucioni, C., Uccelli, A.: Costs and quality of life of multiple sclerosis in Italy. Eur. J. Health. Econ. 7(2 SUPPL.), S45–S54 (2006)CrossRefPubMed
6.
Kobelt, G., Berg, J., Lindgren, P., Berger, K., Elias, W.G., Flachenecker, P., Freidel, M., Konig, N., Limmroth, V., Straube, E.: Costs and quality of life of multiple sclerosis in Germany. Eur. J. Health. Econ. 7(2 SUPPL.), S34–S44 (2006)CrossRefPubMed
7.
Kobelt, G., Berg, J., Lindgren, P., Decoo, D., Guillaume, D., Neymark, N., Sindic, C., Vandegaer, L.: Costs and quality of life for patients with multiple sclerosis in Belgium. Eur. J. Health. Econ. 7(2 Suppl.), S24–S33 (2006)CrossRefPubMed
8.
Kobelt, G., Berg, J., Lindgren, P., Gerfin, A., Lutz, J.: Costs and quality of life of multiple sclerosis in Switzerland. Eur. J. Health. Econ. 7(2 Suppl.), S86–S95 (2006)CrossRefPubMed
9.
Kobelt, G., Berg, J., Lindgren, P., Izquierdo, G., Sanchez-Solino, O., Perez-Miranda, J., Casado, M.A.: Costs and quality of life of multiple sclerosis in Spain. Eur. J. Health. Econ. 7(2 Suppl.), S65–S74 (2006)CrossRefPubMed
10.
Kobelt, G., Berg, J., Lindgren, P., Kerrigan, J., Russell, N., Nixon, R.: Costs and quality of life of multiple sclerosis in the United Kingdom. Eur. J. Health. Econ. 7(Suppl 2), S96–S104 (2006)CrossRefPubMed
11.
Kobelt, G., Berg, J., Lindgren, P., Plesnilla, C., Baumhackl, U., Berger, T., Kolleger, H., Vass, K.: Costs and quality of life of multiple sclerosis in Austria. Eur. J. Health. Econ. 7(Suppl 2), S14–S23 (2006)CrossRefPubMed
12.
Berg, J., Lindgren, P., Fredrikson, S., Kobelt, G.: Costs and quality of life of multiple sclerosis in Sweden. Eur. J. Health. Econ. 7(Suppl 2), S75–S85 (2006)CrossRefPubMed
13.
Kobelt, G., Berg, J., Lindgren, P., Fredrikson, S., Jo¨nsson, B.: Costs and quality of life of patients with multiple sclerosis in Europe. J. Neurol. Neurosurg. Psychiatry. 77, 918–926 (2006)CrossRefPubMedPubMedCentral
14.
McCrone, P., Heslin, M., Knapp, M., Bull, P., Thompson, A.: Multiple sclerosis in the UK: Service use, costs, quality of life and disability. Pharmacoeconomics. 26(10), 847–860 (2008)CrossRefPubMed
15.
National Institute for Clinical Excellence: Beta Interferon and Glatarimer Acetate for the Treatment of Multiple Sclerosis. Guidance No. 32. National Institute for Clinical Excellence, London (2002)
16.
National Institute for Health and Clinical Excellence: Natalizumab for the Treatment of Adults with Highly Active Relapsing-Remitting Multiple Sclerosis. Guidance No. TA127. National Institute for Health and Clinical Excellence, London (2007)
17.
National Institute for Health and Clinical Excellence: Fingolimod for the Treatment of Highly Active Relapsing-Remitting Multiple Sclerosis. TA254. National Institute for Health and Clinical Excellence, London (2012)
18.
McCabe, C., Chilcott, J., Claxton, K., Tappenden, P., Cooper, C., Roberts, J., Cooper, N., Abrams, K.: Continuing the multiple sclerosis risk sharing scheme is unjustified. BMJ 340, c1786 (2010)CrossRefPubMed
19.
Chilcott, J., McCabe, C., Tappenden, P., O’Hagan, A., Cooper, N.J., Abrams, K., Claxton, K.: Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. BMJ 326(7388), 522–525 (2003)CrossRefPubMedPubMedCentral
20.
21.
Hawton, A., Shearer, J., Goodwin, E., Green, C.: Squinting through layers of fog: assessing the cost effectiveness of treatments for multiple sclerosis. Appl. Health. Econ. Health. Policy. 11, 331–341 (2013)CrossRefPubMed
22.
Owens, T., Evangelou, N., Whynes, D.: Rationing and deprivation: disease-modifying therapies for multiple sclerosis in the United Kingdom. Eur. J. Health. Econ. 14, 315–321 (2013)CrossRefPubMed
23.
Zajicek, J., Ingram, W., Vickery, J., Creanor, S., Wright, D., Hobart, J.: Patient-orientated longitudinal study of multiple sclerosis in south west England (The South West Impact of Multiple Sclerosis Project, SWIMS 1: protocol and baseline characteristics of cohort. BMC. Neurol 10, 88 (2010)CrossRefPubMedPubMedCentral
24.
Zajicek, J., Freeman, J., Porter, B.: Multiple Sclerosis: A Practical Manual. Oxford University Press, Oxford (2007)CrossRef
25.
Oleen-Burkey, M., Castelli-Haley, J., Lage, M., Johnson, K.: Burden of a multiple sclerosis relapse: the patient’s perspective. Patient 5(1), 57–69 (2012)CrossRefPubMed
26.
Poser, C., Paty, D., Scheinburg, L.: New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13, 227–231 (1983)CrossRefPubMed
27.
Confavreux, C., Compston, A.: The Natural history of Multiple Sclerosis. In: McAlpine’s Multiple Sclerosis. Churchill Livingstone Elsevier, Philadelphia (2006)
28.
Tyas, D., Kerrigan, J., Russell, N., Nixon, R.: The distribution of the cost of multiple sclerosis in the UK: how do costs vary by illness severity? Value. Health. 10(5), 386–389 (2007)CrossRefPubMed
29.
Patwardhan, M., Matchar, D., Samsa, G., McCrory, D., Williams, R., Li, T.: Cost of multiple sclerosis by level of disability: a review of literature. Mult. Scler. 11, 232–239 (2005)CrossRefPubMed
30.
O’Brien, J., Ward, A., Patrick, A., et al.: Cost of managing an episode or relapse in multiple sclerosis in the United States. BMC. Health. Serv. Res. 3(1), 17 (2003)CrossRefPubMedPubMedCentral
31.
Amato, M., Battaglia, M., Caputo, D., Fattore, G., Gerzeli, S., Pitaro, M., Reggio, R., Trajano, M.: The costs of multiple sclerosis: a cross-sectional, multi-center, cost-of-illness study in Italy. J. Neurol. 249, 152–163 (2002)CrossRefPubMed
32.
Parkin, D., Jacoby, A., McNamee, P., Miller, P., Thomas, S., Bates, D.: Treatment of multiple sclerosis with interferon beta: An appraisal of cost-effectiveness and quality of life. J. Neurol. Neurosurg. Psychiatry. 68(2), 144–149 (2000)CrossRefPubMedPubMedCentral
33.
Grima, D.T., Torrance, G.W., Francis, G., Rice, G., Rosner, A.J., Lafortune, L.: Cost and health related quality of life consequences of multiple sclerosis. Mult Scler 6(2), 91–98 (2000)CrossRefPubMed
34.
Naci, H., Fleurence, R., Birt, J., Duhig, A.: Economic burden of multiple sclerosis. a systematic review of the literature. Pharmacoeconomics 28(5), 363–379 (2010)CrossRefPubMed
35.
Orme, M., Kerrigan, J., Tyas, D., Russell, N., Nixon, R.: The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value. Health. 10(1), 54–60 (2007)CrossRefPubMed
36.
Zajicek, J., Ingram, W., Vickery, J., Creanor, S., Wright, D., Hobart, J.: Patient-orientated longitudinal study of multiple sclerosis in south west England (The South West Impact of Multiple Sclerosis Project, SWIMS) 1: protocol and baseline characteristics of cohort. BMC. Neurol. 10, 88 (2010)CrossRefPubMedPubMedCentral
37.
Kurtzke, J.: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33, 1444–1452 (1983)CrossRefPubMed
38.
Curtis, L.: Unit Costs of Health and Social Care 2013. Personal Social Services Research Unit. University of Kent, Canterbury (2013)
39.
Department of Health: Reference Costs 2011–12. Department of Health, London (2012)
40.
41.
Fox, C., Bensa, S., Bray, I., Zajicek, J.: The epidemiology of multiple sclerosis in Devon: a comparison of new and old classification criteria. J. Neurol. Neurosurg. Psychiatry. 75, 56–60 (2004)PubMedPubMedCentral
42.
Robertson, N., Deans, J., Fraser, M., et al.: Multiple sclerosis in the North Cambridgeshire districts of East Anglia. J. Neurol. Neurosurg. Psychiatry. 59, 71–76 (1995)CrossRefPubMedPubMedCentral
43.
Ford, H., Gerry, E., Airey, C., et al.: The prevalence of multiple sclerosis in the Leeds Health Authority. J. Neurol. Neurosurg. Psychiatry. 64, 605–610 (1998)CrossRefPubMedPubMedCentral
44.
Forbes, R.B., Wilson, S., Swingler, R.J.: The prevalence of multiple sclerosis in Tayside, Scotland: do latitudinal gradients really exist? J. Neurol. 246, 1033–1040 (1999)CrossRefPubMed
45.
McDonnell, G., Hawkins, S.: An epidemiologic study of multiple sclerosis in Northern Ireland. Neurology 50, 423–428 (1998)CrossRefPubMed
46.
Forbes, R.B., Swingler, R.J., Hawkins, S., et al.: An epidemiological study of multiple sclerosis in Northern Ireland. Neurology 52, 214–218 (1999)CrossRef
47.
Ford, D., Jones, K., Middleton, R., Lockhart-Jones, H., Maramba, I., Noble, G., Osborne, L., Lyons, R.: The feasibility of collecting information from people with Multiple Sclerosis for the UK MS Register via a web portal: characterising a cohort of people with MS. BMC. Med. Inform. Decis. Mak. 12, 73 (2012)CrossRefPubMedPubMedCentral
48.
Kobelt, G., Berg, J., Lindgren, P., Jonsson, B.: Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis. Eur. J. Health. Econ. 7(Suppl 2), S5–S13 (2006)CrossRefPubMed
Metadata
Title
Multiple sclerosis: relapses, resource use, and costs
Authors
A. J. Hawton
C. Green
Publication date
01-09-2016
Publisher
Springer Berlin Heidelberg
Published in
The European Journal of Health Economics / Issue 7/2016
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-015-0728-3

Other articles of this Issue 7/2016

The European Journal of Health Economics 7/2016 Go to the issue

Original Paper

Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin–paclitaxel

Original Paper

OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales

Original Paper

Unchained melody: revisiting the estimation of SF-6D values

Original Paper

Overpaying morbidity adjusters in risk equalization models

Original Paper

Comparative analysis of decision maker preferences for equity/efficiency attributes in reimbursement decisions in three European countries

Editorial

Improving health care systems by building ‘more Europe’